Roche said Foundation Medicine will acquire SAGA Diagnostics in a deal valued at up to $595 million, expanding its molecular residual disease (MRD) portfolio. Foundation will integrate SAGA’s Pathlight MRD platform, which combines whole-genome sequencing with digital PCR for ultra-sensitive detection and tracking of structural variants. Roche reported that Pathlight is already covered by Medicare for monitoring cancer recurrence in early-stage breast cancer in the US. The companies said Pathlight is available in the US with plans to expand internationally, and that Foundation intends to use Roche technologies such as AXELIOS sequencing and digital LightCycler PCR to support a more decentralized MRD offering. The acquisition is expected to close by the third quarter of 2026, subject to regulatory approvals.